Business Context and Reporting Period
This Form 8-K reports the consummation of a merger between Reneo Pharmaceuticals, Inc. (the "Predecessor") and OnKure, Inc. ("Legacy OnKure") on October 4, 2024. Following the transaction, the Predecessor changed its name to OnKure Therapeutics, Inc. and reclassified its common stock as Class A Common Stock, trading under the ticker symbol OKUR on the Nasdaq Stock Market. Legacy OnKure became a wholly-owned subsidiary of the Combined Company. The filing also details a concurrent Private Investment in Public Equity (PIPE) transaction.
Key Financial Metrics
Capitalization and Liquidity:
- PIPE Investment: Raised approximately $65.0 million in gross proceeds from PIPE Investors for 2,839,005 shares of Class A Common Stock at approximately $22.895 per share.
- Cash Position: As of June 30, 2024, Legacy OnKure held $18.6 million in cash and cash equivalents. Management believes the combined cash resources (including PIPE proceeds) are sufficient to fund operations into the fourth quarter of 2026.
- Accumulated Deficit: Legacy OnKure reported an accumulated deficit of $125.7 million as of June 30, 2024.
- Share Count: Immediately post-transaction, there were approximately 12,652,811 shares of Class A Common Stock and 686,527 shares of non-voting Class B Common Stock outstanding.
Historical Performance (Legacy OnKure):
- Revenue: $0. The company has not generated any revenue from product sales.
- Net Loss (Six Months Ended June 30, 2024): $23.7 million.
- Net Loss (Year Ended Dec 31, 2023): $35.3 million.
- Operating Expenses (Six Months Ended June 30, 2024): $24.2 million total, comprised of $19.3 million in Research and Development (R&D) and $4.9 million in General and Administrative (G&A) expenses.
- Cash Flow: Net cash used in operating activities was $17.1 million for the six months ended June 30, 2024.
Material Changes Versus Prior Period
Operational and Structural Changes:
- Corporate Identity: The company transitioned from Reneo Pharmaceuticals to OnKure Therapeutics, Inc., adopting a new ticker symbol (OKUR) and a 1:10 reverse stock split.
- Leadership: The board and executive team were reconstituted. Nicholas Saccomano, Ph.D., was appointed CEO; Jason Leverone, CPA, as CFO; Samuel Agresta, M.D., as CMO; and Dylan Hartley, Ph.D., as CSO.
- Expense Trends: R&D expenses increased by $4.3 million (28%) in the six months ended June 30, 2024, compared to the same period in 2023, driven by increased clinical trial costs and personnel-related expenses. G&A expenses increased by $2.5 million, primarily due to legal service costs related to the merger.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- Lead Candidate: OKI-219, a highly selective inhibitor of PI3Kα H1047R mutation, is in a Phase 1 monotherapy dose-escalation trial. Early clinical data is anticipated in the fourth quarter of 2024.
- Future Funding: The company expects to continue incurring significant operating losses and negative cash flows. It anticipates requiring substantial additional capital to advance clinical trials and commercialize products.
Risks and Contingencies:
- Legal Proceedings: Two shareholder complaints were filed in the Supreme Court of the State of New York (September 2024) alleging misrepresentations in the proxy statement regarding financial projections and valuation. The company intends to vigorously defend these claims.
- Going Concern: Prior to the merger and PIPE, there was substantial doubt about the company's ability to continue as a going concern. Post-transaction, management believes liquidity is sufficient for at least 12 months.
- Development Risks: Significant risks exist regarding the clinical development, regulatory approval, and commercialization of product candidates, including the potential for trial delays or failure.
Investor Verification Checklist
- Verify the final cash balance post-transaction and the specific runway timeline (Q4 2026) against current burn rates.
- Review the status of the pending shareholder litigation in New York regarding the merger proxy statement disclosures.
- Monitor the anticipated release of early clinical data for OKI-219 in Q4 2024.
- Confirm the vesting schedules and terms of the new executive employment agreements and equity awards granted on the closing date.
- Assess the dilution impact of the PIPE investment and the 1:10 reverse stock split on existing shareholders.